Cryosite (CTE.AX) Aktsia Kursus
Cryosite Kursus
Viimase 19 aasta jooksul kasvas Cryosite käive 6,9 % aastas ja jõudis 16,70 M AUD-ni. Kasum aktsia kohta kasvas 4,1 % aastas viimase 19 aasta jooksul. Cryosite netomarginaal 13,4 % on tõusnud võrreldes 11,6 %-ga mõni aasta tagasi. Tänase hinna juures on dividenditootlus umbes 1,64 %. Väljamaksesuhe on umbes 91 % kasumist. Dividend kasvas 5,5 % aastas viimase 13 aasta jooksul.
Cryosite aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Cryosite ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Cryosite aktsia kohta
The business model of Cryosite Ltd focuses on providing biobanking and cell therapy services. Cryosite specializes in the collection, storage, and distribution of human biological samples such as cord blood, tissue, and cells for medical and research purposes. The company allows individuals and families to preserve cord blood stem cells for potential future use in regenerative medicine. Cryosite also offers cell therapy manufacturing services to support personalized medicine and clinical trials. With its expertise and advanced technology, Cryosite aims to contribute to advancements in medical treatments and research, offering peace of mind to those seeking to preserve their biological materials.
Cryosite Ltd is primarily active in the biomedical and life sciences industries.
The main competitors of Cryosite Ltd in the market are companies like Stemlife, Singapore Cord Blood Bank, and CordLife Group Limited.
Cryosite Ltd, a reputable Australian company, has an intriguing history and background. Established in 2000, Cryosite has played a pivotal role in the field of biomedical services. The company specializes in secure storage and transportation of precious biological samples, supporting medical research, clinical trials, and stem cell transplant programs. With state-of-the-art facilities and stringent quality control measures, Cryosite has gained recognition as a trusted partner for numerous healthcare institutions and research organizations globally. Over the years, Cryosite Ltd has showcased its expertise in preserving and managing these life-changing resources, contributing significantly to advancements in healthcare and cutting-edge research.
Cryosite Ltd has achieved several significant milestones. Firstly, the company successfully established itself as a leading provider of comprehensive storage solutions for stem cells, reproductive tissues, and cord blood in Australia. Additionally, Cryosite Ltd expanded its services by offering advanced cryopreservation techniques, ensuring the long-term viability of stored materials. The company's commitment to quality led to accreditation by the Therapeutic Goods Administration (TGA) and attainment of ISO 9001 certification. Furthermore, Cryosite Ltd expanded its client base, attracting partnerships with major healthcare institutions and research organizations. These milestones demonstrate Cryosite Ltd's success in delivering trusted and state-of-the-art cryogenic storage services to its clients.
Cryosite Ltd primarily operates in Australia and New Zealand.
Cryosite Ltd is a leading company that values integrity, reliability, and innovation. With a strong corporate philosophy focused on providing premium services and solutions in the field of biobanking and reproductive services, Cryosite is committed to excellence. The company strives to ensure the utmost trust and transparency in all its operations, delivering high-quality cryopreservation services, cord blood banking, and stem cell research facilities. Cryosite Ltd continuously pushes boundaries through cutting-edge technology and strategic partnerships, aiming to meet the evolving needs of its customers and make a positive impact in the healthcare industry.
Praeguse kursiga kaubeldakse Cryosite aktsiaga 0,75 EUR (1,22 AUD) juures.
Cryosite aktsia (CTE.AX) on noteeritud 1 börsil, sh: ASX (CTE.AX).
Cryosite Ltd is an Australian company that has been operating in the field of biological material storage for over 15 years. With a wide range of services and products, the company has established itself as a leading provider of cryo-storage solutions in Australia.
Cryosite käive on 16,70 M AUD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
Cryosite kasum on 2,24 M AUD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Cryosite jaoks on praegu 28,49. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Cryosite aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Cryosite jaoks on praegu 3,81. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Cryosite aktsia jaoks.
Eulpooli kvaliteedinäitaja Cryosite jaoks on 7/10.
Cryosite ISIN on AU000000CTE1. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Cryosite WKN on 621943. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Cryosite ticker on CTE.AX. Ticker-sümbol kasutatakse Cryosite aktsiate kauplemiseks börsil.
Cryosite aktsia
Cryosite konkurendid
Cryosite Börsiticker
Cryosite FIGI
Kõik teised näitajad ja analüüsid Cryosite kohta sügavamalt
Meie Cryosite-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Cryosite. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: